Neurofibromatosis type 1 and malignancy in childhood

被引:46
|
作者
Varan, A. [1 ]
Sen, H. [1 ]
Aydin, B. [1 ]
Yalcin, B. [1 ]
Kutluk, T. [1 ]
Akyuz, C. [1 ]
机构
[1] Hacettepe Univ, Dept Pediat Oncol, Inst Canc, TR-06100 Ankara, Turkey
关键词
brain tumors; malignant peripheral nerve sheath tumors; neurofibromatosis; outcome; NERVE SHEATH TUMORS; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; FOLLOW-UP; CHILDREN; RHABDOMYOSARCOMA;
D O I
10.1111/cge.12625
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Neurofibromatosis type 1 (NF1) is an autosomal dominant hereditary neurocutaneous syndrome characterized by multi-system involvement and an increased incidence of both benign and malignant tumors. In this study, we evaluated the clinical presentation and prognosis of NF1 and malignancy. Between 1975 and 2013, 26 (5%) of the 473 patients with NF1 at our center developed non-neurofibroma neoplasms. The patient files of 26 subjects with tumors, other than optic glioma, were analyzed retrospectively to evaluate clinical features and treatment results. The age at diagnosis of NF1 ranged from 3 months to 16 years (median 5.5 years). The age range at tumor diagnosis was 1.5-33 years (median 8 years) in these 26 patients. The tumor histological subtypes included the following: 12 soft-tissue tumors (6 malignant peripheral nerve sheath tumors (MPNST), 5 rhabdomyosarcomas (RMS) and 1 malignant fibrous histiocytoma), 11 brain tumors (6 low-grade gliomas, 3 high-grade gliomas, and 2 medulloblastoma), 2 neuroblastomas and 1 non-Hodgkin's lymphoma. Twelve of 26 patients were alive at the time of the study. Although benign brain tumors with NF1 are more common, high-grade brain tumors also occur. Thus, careful and regular follow-up is crucial for early detection of malignancy in NF1 patients.
引用
收藏
页码:341 / 345
页数:5
相关论文
共 50 条
  • [1] What Is the Malignancy Risk in Neurofibromatosis Type 1?
    Gareth, D.
    Evans, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (17) : 1967 - +
  • [2] Therapeutics for Childhood Neurofibromatosis Type 1 and Type 2
    Ardern-Holmes, Simone L.
    North, Kathryn N.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2011, 13 (06) : 529 - 543
  • [3] Neurofibromatosis type 1 and associated malignancies
    Yohay, Kaleb
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2009, 9 (03) : 247 - 253
  • [4] Endocrine Implications of Neurofibromatosis 1 in Childhood
    Bizzarri, Carla
    Bottaro, Giorgia
    HORMONE RESEARCH IN PAEDIATRICS, 2015, 83 (04): : 232 - 241
  • [5] Malignancies in Chinese patients with neurofibromatosis type 1
    Cheuk, Daniel K. L.
    Chiang, Alan K. S.
    Ha, S. Y.
    Chan, Godfrey C. F.
    HONG KONG MEDICAL JOURNAL, 2013, 19 (01) : 42 - 49
  • [6] Treatment of Neurofibromatosis Type 1
    Sabatini, Caterina
    Milani, Donatella
    Menni, Francesca
    Tadini, Gianluca
    Esposito, Susanna
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2015, 17 (06) : 1 - 11
  • [7] Neurofibromatosis Type 1: Review and Update on Emerging Therapies
    Karaconji, Tanya
    Whist, Eline
    Jamieson, Robyn V.
    Flaherty, Maree P.
    Grigg, John R. B.
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2019, 8 (01): : 62 - 72
  • [8] NEUROFIBROMATOSIS TYPE-1 AND CHILDHOOD-CANCER
    MATSUI, I
    TANIMURA, M
    KOBAYASHI, N
    SAWADA, T
    NAGAHARA, N
    AKATSUKA, J
    CANCER, 1993, 72 (09) : 2746 - 2754
  • [9] Optic Gliomas in Neurofibromatosis Type 1
    Parkhurst, Emily
    Abboy, Sridevi
    JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS, 2016, 53 (06) : 334 - 338
  • [10] LETHAL MANIFESTATIONS OF NEUROFIBROMATOSIS TYPE-1 IN CHILDHOOD
    KOSZYCA, B
    MOORE, L
    BYARD, RW
    PEDIATRIC PATHOLOGY, 1993, 13 (05): : 573 - 581